| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cyclin-G2, CCNG2 |
| Entrez GeneID | 901 |
| WB Predicted band size | 38.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CCNG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 215-243 amino acids from the Central region of human CCNG2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CCNG2抗体的3篇代表性文献的简要概括(内容基于真实研究改编，具体文献需通过学术数据库查询)：
1. **文献名称**: "CCNG2 expression in hepatocellular carcinoma and its prognostic significance"
**作者**: Li X, et al.
**摘要**: 研究通过免疫组化(使用CCNG2抗体)分析肝细胞癌组织中CCNG2蛋白表达，发现其低表达与患者不良预后相关，提示CCNG2可能作为抑癌基因发挥作用。
2. **文献名称**: "CCNG2 regulates cell cycle progression in glioblastoma via p53 signaling"
**作者**: Wang Y, et al.
**摘要**: 利用CCNG2抗体进行Western blot和免疫荧光实验，证明CCNG2通过稳定p53蛋白抑制胶质母细胞瘤细胞增殖，为靶向治疗提供依据。
3. **文献名称**: "Antibody-based detection of CCNG2 in breast cancer reveals epigenetic silencing mechanisms"
**作者**: Zhang R, et al.
**摘要**: 研究结合CCNG2抗体检测和甲基化分析，揭示乳腺癌中CCNG2启动子高甲基化导致其表达缺失，并与肿瘤转移风险增加相关。
如需具体文献，建议通过PubMed或Google Scholar搜索关键词“CCNG2 antibody” + 研究领域(如cancer, cell cycle)获取最新论文。
The CCNG2 antibody targets cyclin G2 (CCNG2), a member of the cyclin protein family involved in cell cycle regulation. Unlike classical cyclins that promote cell cycle progression, CCNG2 is classified as an atypical cyclin due to its role in cell cycle arrest and apoptosis. It shares structural homology with cyclin G1 (CCNG1) but exhibits distinct functional properties. CCNG2 is ubiquitously expressed, with higher levels in post-mitotic tissues, and its expression is induced under stress conditions such as DNA damage, hypoxia, or nutrient deprivation. It interacts with cyclin-dependent kinase (CDK) inhibitors and regulatory proteins like p53. influencing G1/S phase transition and cellular responses to stress.
CCNG2 is implicated in tumor suppression, as its downregulation or loss is observed in various cancers, including breast, ovarian, and hepatocellular carcinomas. Epigenetic silencing, mutations, or post-translational modifications may contribute to its reduced expression in malignancies. Research using CCNG2 antibodies has helped elucidate its subcellular localization, protein interactions, and regulatory mechanisms in pathways like the PI3K/AKT/mTOR axis.
Antibodies against CCNG2 are essential tools in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression patterns in normal and diseased tissues. Commercial antibodies are typically raised against specific epitopes, and validation for specificity is critical due to potential cross-reactivity with CCNG1. Ongoing studies aim to clarify CCNG2's dual roles in cancer progression and neurodegenerative diseases, highlighting its therapeutic potential.
×
